61: A Case of Antibody-Mediated Hemolysis in a Liver Transplant Recipient due to Passenger Lymphocyte Syndrome

Kallan, Jamie E.; Draper, Norman R.; Vinson, Leslie; Moskowitz, Eliza E.; Berg, Mary

doi:10.1093/ajcp/143.suppl1.034

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Medical therapy was limited to a median of 2 PRBC transfusions, and no subject required other treatment. This is in contrast to adult studies reporting significant PRBC requirements (6 and up to 24 units of PRBC) (7,14,(24)(25)(26)28,29), steroids (7), intravenous immunoglobulin, or anti-CD20 antibodies (4,5,10,13,14,23). The limited pediatric cases of PLS following liver transplant in the current literature describe milder courses as well, requiring no support in 1 case (8), only hydration and folic acid in 1 case (14), and PRBC in the other 2 (7,8).…”

Section: Discussioncontrasting

confidence: 73%

Passenger Lymphocyte Syndrome After Pediatric Liver Transplantation

Woolfson

Vandriel

Stephens

et al. 2019

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

Background: Passenger lymphocyte syndrome (PLS) is a less known etiology of acute onset anemia following ABO-compatible (ABO-c) liver transplantation (LT). Available literature on PLS after pediatric LT is limited. Therefore, we evaluated the prevalence, clinical course, and risk factors of PLS in children following ABO-c LT. Methods: A single-center retrospective review of all children who underwent LT between 2000 and 2017 was performed. PLS was defined as a drop-in hemoglobin >20 g/L within 30 days of LT, with positive direct antiglobulin test and 1 laboratory test confirming hemolysis. Chi square and student t tests compared variables between subjects with and without PLS. Results: Amongst 333 pediatric LT performed, 51 children received an ABO-c graft. PLS was diagnosed in 7 (14%) subjects at a median of 10 days after LT. There were no significant differences in patient demographics, graft type, or immunosuppression between those who did and did not develop PLS. Recipient blood group A+ receiving a donor O+ graft was a risk factor for PLS (P = 0.015). All PLS subjects recovered with blood transfusions (median 2), and no additional interventions. Three subjects initially received recipient (instead of donor) blood group red cells. Conclusions: We report a 14% prevalence of PLS following pediatric ABO-c LT. Recipient blood group A+ receiving a donor O+ graft is a risk factor for PLS. Recognition of PLS as a cause of early acute anemia in pediatric ABO-c LT enables timely transfusion with donor (rather than recipient) blood group red cells.

show abstract